International Scientific Expert Panel (iSEP)

Members of the iSEP, who are internationally recognized experts in the fields of epigenetics and oncology, provide 4SC with consultancy on research and clinical product development.

Prof. Thomas Jenuwein, Ph.D.

During the last 20 years breakthrough discoveries in epigenetic research have transformed our knowledge of normal and perturbed development. To translate these insights from the bench to the clinic will improve human health and offer novel avenues to combat disease.
Prof. Thomas Jenuwein, Ph.D. | Director and Senior Group Leader, Max Planck Institute of Immunobiology and Epigenetics

Short Biography

Thomas Jenuwein graduated in 1987 from the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany) working on fos oncogenes in the laboratory of Rolf Müller. He performed postdoctoral studies on the IgH enhancer with Rudolf Grosschedl at the University of California San Francisco (UCSF, USA). As an independent group leader at the Institute of Molecular Pathology (IMP) in Vienna (Austria) from 1993 to 2008, he focused his research to chromatin regulation. In 2000, he discovered the first histone lysine methyltransferase. He is now director at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg (Germany) where he heads the department of Epigenetics.

Thomas Jenuwein was elected as a member of the European Molecular Biology Organization (EMBO) in 2002 and received the Sir Hans Krebs Medal of the Federation of European Biochemical Societies in 2005 and the Erwin Schrödinger Prize by the Austrian Academy of Sciences in 2007. From 2004 to 2009, he coordinated the EU-funded network of excellence ‘The Epigenome’, which connected more than 80 laboratories in Europe.

He has published more than 120 articles in peer-reviewed journals, has given more than 200 invited lectures and is co-author of the benchmark textbook “Epigenetics” (D. Allis, T. Jenuwein, D. Reinberg and M.L. Caparros, SDHL-Press, 2015).


Research Focus

Epigenetic mechanisms control eukaryotic development beyond DNA-stored information. There are many pathways, such as DNA methylation, nucleosome remodeling, histone modifications, exchange of histone variants and non-coding RNAs that together contribute to differences of the chromatin template. In particular, the great diversity of covalent histone tail modifications has been proposed to reflect an index (‘histone code’) that can stabilize distinct proliferative and developmental options.

Thomas Jenuwein and his team discovered the first histone lysine methyltransferase and then showed that histone lysine methylation represents a central epigenetic modification in eukaryotic chromatin. They are continuing with their analyses on histone lysine methylation to further dissect epigenetic gene regulation and to identify molecular pathways that initiate and maintain heterochromatic domains in mammalian chromatin.


Charles B. Epstein, Ph.D.

4SC's compounds have the potential to have a positive impact in the areas of CTCL and advanced hematological cancer. I'm excited to have the opportunity to contribute my expertise to the realization of this potential.
Charles B. Epstein, Ph.D. | Senior Group Leader, Broad Institute of MIT and Harvard

Short Biography

Charles B. Epstein studied Biology at the Swarthmore College and the University of Chicago (USA). He completed his PhD in Cellular and Molecular Biology with Fred Cross at the Rockefeller University in New York (USA) in 1993 and conducted postdoctoral research as a Damon-Runyon Fellow with Arnold Levine (Princeton University, USA) and Ron Butow (Southwestern Medical Center, Dallas, USA).

After becoming Assistant Professor at the Southwest Medical Center in 1999, Charles B. Epstein joined the pharma industry and worked until 2008 as principal research investigator focused on transcript profiling for biomarker discovery with Sanofi-Aventis Pharmaceuticals. Back to science, he became Program Manager for Epigenomics in 2008 and, since 2014, has served as Senior Group Leader at the Broad Institute of Harvard and MIT in Cambridge (USA).


Research Focus

Charles B. Epstein is an expert in the characterization of the state of the epigenome of low abundance samples using the method of ChIP-seq. His goal is to harness the power of epigenome characterization to better understand cellular diversity in health and disease. In the Epigenomics Program he characterizes chromatin structure and histone modifications in a wide range of cell and tissue types. These modifications influence and respond to gene expression and play a crucial role in cellular differentiation during development, and their dysregulation can be a key driver of drug resistance and disease.

Charles B. Epstein has been responsible for coordinating The Broad’s contributions to NIH-funded epigenomics consortia (ENCODE II, ENCODE III, and NIH Roadmap Epigenomics), as well as to diverse studies of the epigenome in cancer. He has also worked closely with computational biologists to develop innovative methods to ensure data quality.


Prof. Wolff Schmiegel, M.D.

Epigenetic mechanisms are crucial for a better understanding of tumor biology. Gene regulation as well as mechanisms of primary or secondary resistance are important to identify druggable targets also at the epigenetic level. This ultimately can be part of a substantial improvement in personalized medicine.
Prof. Wolff Schmiegel, M.D. | Head of the Department of Medicine, Knappschaftskrankenhaus Bochum GmbH, Ruhr-Universität Bochum and Head of the Department of Gastroenterology / Hepatology, Berufsgenossenschaftliches Klinikum Bergmannsheil, Ruhr-Universität Bochum

Short Biography and Medical Focus

Wolff Schmiegel studied Medicine at the University of Leuven (Belgium), the Ruhr-Universität Bochum (Germany) and the University of Bonn (Germany). He completed his MD in 1978 at the University of Essen (Germany) and obtained a license to practice medicine. Starting in 1978, he worked as Scientific Assistant at the University Medical Center Hamburg-Eppendorf (Germany), specialized in the fields of internal medicine, gastroenterology, endocrinology, hematology and medical oncology, qualified as a professor for internal medicine in 1988, and became Senior Physician in 1990.

In 1993, he became professor for internal medicine, gastroenterology, hepatology and gastroenterological oncology. Also in 1993, he was appointed Professor and Director of the Knappschaftskrankenhaus Bochum GmbH, Ruhr-Universität Bochum (Germany) and, since 2002, has served as Head of the Department of Gastroenterology / Hepatology at the Berufsgenossenschaftliches Klinikum Bergmannsheil, Ruhr-Universität Bochum (Germany).


  • American Gastroenterological Association (AGA), Fellow (AGAF)
  • American Society of Clinical Oncology (ASCO)
  • German Society for Gastroenterology, Digestion and Metabolic Disorders (DGVS)
  • German Society for Internal Medicine (DGIM)
  • German Cancer Society (DKG/AIO), Presidency from 2012 to 2016
  • European Society of Medical Oncology (ESMO)
  • European Society of Digestive Oncology (ESDO)


  • G. E. Konjetzny Award (1988)
  • Dr. Martini Award (1989)
  • Stiftung zur Förderung der Innovation in Wissenschaft und Forschung NRW Award (1994)
  • Charles Moertel Award in Digestive Oncology (IDCA / World Gastroenterology Organization, 2007)
  • Felix Burda Award (2014)


Share this page:

Follow us on: